SCHEMBL6893581

SCHEMBL6893581

Cc1ncc(-c2ccccc2)s1.O=C(Cl)Cl

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 6/20 0.50
ERCC5 P28715 1/20 0.50
FEN1 P39748 1/20 0.50
GSTO1 P78417 1/20 0.47
HCAR2 Q8TDS4 1/20 0.46
CNR1 P21554 1/20 0.46
CCNE1 P24864 1/20 0.46
CDK2 P24941 1/20 0.46
CDK5 Q00535 1/20 0.46
SCD O00767 1/20 0.46
HDAC6 Q9UBN7 2/20 0.43
ACP1 P24666 1/20 0.43
HDAC4 P56524 1/20 0.43
FFAR2 O15552 1/20 0.43
MKNK1 Q9BUB5 1/20 0.43
HSD17B1 P14061 1/20 0.42
HSD17B2 P37059 1/20 0.42
NPC1 O15118 1/20 0.41
ALDH1A1 P00352 1/20 0.41
MAPT P10636 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL146522 0.89 KDR (0.52) KDRERCC5FEN1GSTO1
SCHEMBL5521864 0.85 KDR (0.49) KDRERCC5FEN1HSD17B1HSD17B2
SCHEMBL3937055 0.82 KMO (0.50) KDRHCAR2HDAC6HSD17B1HSD17B2
SCHEMBL10039295 0.79 CSNK2A1 (0.66) KDRHCAR2HDAC6NPC1ALDH1A1
SCHEMBL4979403 0.79 KDR (0.53) KDRERCC5FEN1GSTO1CNR1
SCHEMBL20916718 0.76 NQO2 (0.45) KDRERCC5FEN1GSTO1CNR1
SCHEMBL21228532 0.76 HSD17B1 (0.68) HSD17B1HSD17B2
SCHEMBL1764602 0.76 RAB9A (0.47) CDK2CDK5HDAC6HSD17B1HSD17B2
SCHEMBL29914706 0.76 HSD17B1 (0.68) HSD17B1HSD17B2
SCHEMBL24112826 0.75 KDR (0.53) KDRERCC5FEN1GSTO1CNR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040180887-A1 N-aroyl cyclic amine derivatives as orexin receptor antagonists SMITHKLINE BEECHAM LIMITED (GB) 2004-09-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040180887-A1 N-aroyl cyclic amine derivatives as orexin receptor antagonists HCRTR2, HCRTR1, OXTR KDR 855/4885ERCC5 4598/4885FEN1 4674/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.